NCT00518284

Prevention of Restenosis Following Revascularization

A Phase II Trial of ABI-007 (Paclitaxel Albumin-bound Particles) for the Prevention of Restenosis Following Revascularization of the Superficial Femoral Artery (SFA)

• Status: Terminated
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 6 (actual)
• Sponsor: Celgene Corporation · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to investigate the prevention of Restenosis following Revascularization of the superficial Femoral Artery (SFA)

Conditions

• Vascular Disease, Peripheral

Interventions

Type	Name	Description
DRUG	Nanoparticle Paclitaxel	Nanoparticle albumin-bound paclitaxel, 45 mg/m\^2.

Timeline

• Start date: 2008-01-01
• Primary completion: 2009-08-01
• Completion: 2009-09-01
• First posted: 2007-08-20
• Last updated: 2012-03-13
• Results posted: 2012-03-13

Locations

7 sites across 1 country: United States